The chief executive said Biogen doesn’t really want to do one deal that takes all of the company’s cash flow and that there is an interest in building the pipeline with multiple assets.

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of ...

To chart that change, Biogen is focusing on building up four recent drug launches, reprioritizing its pipeline and cutting operating expenses, Viehbacher said. On the last point, Biogen has been ...

Building tools for clinicians The explosion ... So, another effort from Biogen is a web-platform and app they’ve developed called Neurodiem, which helps CNS specialists specifically keep up ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...